Business Description
4D Molecular Therapeutics is a late-stage biotech company based in Emeryville, California, with operations in the Netherlands, that develops gene therapy treatments using its proprietary vector discovery platform. Its most advanced therapy, 4D-150, targets retinal diseases such as wet age-related macular degeneration and diabetic macular edema by delivering long-lasting treatment through a single eye injection. The company has additional programs in earlier stages of development targeting cystic fibrosis, geographic atrophy, and a rare lung disease, and works in partnership with Otsuka Pharmaceutical.
